Supernus Pharmaceuticals, Inc. v. TWi Pharmaceuticals, Inc., No. 17-2513 (Fed. Cir. Sept. 6, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

TWi Pharmaceuticals, Inc. (“TWi”) appeals from a de- cision of the United States District Court for the District of New Jersey holding, after bench trial, that Supernus Pharmaceuticals, Inc.’s (“Supernus”) U.S. Patent Nos. 7,722,898 (“the ’898 patent”), 7,910,131 (“the ’131 p a- tent”), and 8,821,930 (“the ’930 patent) (collectively, “the asserted patents”) are not invalid and would be infringed. Supernus Pharms., Inc. v. TWi Pharms., Inc. , 265 F. Supp. 3d 490 (D.N.J. 2017). For the following reasons, we affirm. I. BACKGROUND A.